AVALO THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements
AVALO THERAPEUTICS, INC. (AVTX) reported Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements of 0 shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-18.
Discontinued › Notes › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements · last filed 2019-03-18
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2018-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2017-09-30 was 25.02K shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for the quarter ending 2016-09-30 was 0.00 shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2018 was 0.00 shares, a 100.00% decline from fiscal 2017.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2017 was 61.51K shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2016 was 0.00 shares.
- AVALO THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of share-based payment arrangements for fiscal 2015 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 3 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 9 month | Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements 12 month |
|---|---|---|---|
| 2018-12-31 | 0.00 shares 10-K · filed 2019-03-18 | ||
| 2018-09-30 | 0.00 shares 10-Q · filed 2018-11-13 | 0.00 shares 10-Q · filed 2018-11-13 | |
| 2017-12-31 | 61.51K shares 10-K · filed 2019-03-18 | ||
| 2017-09-30 | 25.02K shares 10-Q · filed 2018-11-13 | 7.64K shares 10-Q · filed 2018-11-13 | |
| 2016-12-31 | 0.00 shares 10-K · filed 2018-04-02 | ||
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | |
| 2015-12-31 | 0.00 shares 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |